San Francisco startup Radical Numerics raised $50 million for developing AI models focused on biology, aiming to create 'general biological intelligence'. This investment reflects the increasing interest in using AI for drug discovery and detecting biological threats.
Radical Numerics secured a $50 million seed funding round, supported by Emergence Capital and others.
Notable early investor includes Stripe co-founder Patrick Collison.
The company aims to develop AI models that can reason across biological data such as DNA and RNA.
Their goal is to accelerate advancements in drug discovery and cancer diagnostics.
Along with the funding announcement, Radical Numerics previewed Omnii—their next-gen genome language model.
This model represents their ambition to achieve 'general biological intelligence' in biological systems.
The investment trend highlights a growing interest in frontier AI applications in healthcare and biosecurity.
As AI advances, the potential for both positive and negative impacts on biology raises ethical considerations.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
San Francisco startup Radical Numerics raised $50 million for developing AI models focused on biology, aiming to create 'general biological intelligence'. This investment reflects the increasing interest in using AI for drug discovery and detecting biological threats.